PATENT CLAIM ANALYSIS

Application Number: 16032812
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["436", "547000"]

Abstract:
The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.

Claim (Index 18):
The method of  claim 1 , wherein said method comprises inhibiting or reducing the severity of secondary phase neuronal damage associated with optic neuropathy.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 95.0
- Lexical Diversity: 1.13043
- Patent Class: 436.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['10807414', '14812566', '11034262', '09765644', '14403523']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6733505047639614
- 35 USC 102 Novelty (BERT): 0.5142401365395608
- Combined Prediction Score: 0.6574394679415214
- Mean Citation Score: 304.389314
- Max Citation Score: 318.16144
- Similarity Product: 236.3385850426484

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test